Kristen K Flaharty
Pharmacy in Fort Myers, FL
License number
Utah 152794-1701
Issued Date
Mar 25, 1992
Expiration Date
Sep 30, 2011
Category
Pharmacy
Type
Pharmacist
Address
Address
Fort Myers, FL
Professional information
Combination Therapy For Inhibition Of Platelet Aggregation
US Patent:
2010004, Feb 18, 2010
Filed:
Aug 12, 2009
Appl. No.:
12/540062
Inventors:
R. Stephen PORTER - Franklin TN, US
Kristen K. Flaharty - Fort Myers FL, US
James E. Tcheng - Durham NC, US
John W. Ferkany - Brighton MA, US
Kristen K. Flaharty - Fort Myers FL, US
James E. Tcheng - Durham NC, US
John W. Ferkany - Brighton MA, US
International Classification:
A61K 38/16, A61K 31/727
US Classification:
514 8, 514 56
Abstract:
The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.
Combination Therapy For Inhibition Of Platelet Aggregation
US Patent:
2007008, Apr 12, 2007
Filed:
Sep 5, 2006
Appl. No.:
11/515596
Inventors:
R. Porter - Franklin TN, US
Kristen Flaharty - Fort Myers FL, US
James Tcheng - Durham NC, US
John Ferkany - Brighton MA, US
Kristen Flaharty - Fort Myers FL, US
James Tcheng - Durham NC, US
John Ferkany - Brighton MA, US
International Classification:
A61K 38/12, A61K 38/06, A61K 38/05, A61K 31/727, A61K 31/5513, A61K 31/5377, A61K 31/445
US Classification:
514009000, 514018000, 514317000, 514221000, 514326000, 514232500, 514056000
Abstract:
The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral administration of the same or a different platelet activation or aggregation inhibitor. The treatment may commence prior to a medical or surgical procedure or after the outbreak of an adverse medical condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter.